The expression of JAK2 mutation is seen in all conditions, EXCEPT:
**Core Concept**
The JAK2 mutation is a gain-of-function mutation in the JAK2 gene, leading to constitutive activation of the JAK-STAT signaling pathway. This mutation is commonly associated with myeloproliferative neoplasms (MPNs) and is a key driver of the pathogenesis of these diseases.
**Why the Correct Answer is Right**
The JAK2 mutation is a specific point mutation (V617F) that leads to the substitution of valine with phenylalanine at position 617 in the JAK2 protein. This mutation results in the constitutive activation of the JAK-STAT pathway, which promotes cell proliferation and survival. The JAK2 mutation is a key driver of the pathogenesis of MPNs, including polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF).
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because JAK2 mutation is indeed associated with myeloproliferative neoplasms, including PV, ET, and PMF.
* **Option B:** This option is incorrect because JAK2 mutation is not typically associated with acute myeloid leukemia (AML), although it can be present in some cases.
* **Option C:** This option is incorrect because JAK2 mutation is not typically associated with lymphomas, although it can be present in some cases of lymphoproliferative disorders.
* **Option D:** This option is incorrect because JAK2 mutation is not typically associated with chronic lymphocytic leukemia (CLL), although it can be present in some cases.
**Clinical Pearl / High-Yield Fact**
The JAK2 mutation is a specific and sensitive marker for the diagnosis of MPNs, particularly PV, ET, and PMF. However, it is essential to note that the presence of the JAK2 mutation does not exclude other myeloid neoplasms, and a comprehensive diagnostic workup is necessary to establish a definitive diagnosis.
**Correct Answer:** B